TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20113920
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine coadministered with dTpa-IPV
Study: 20113920
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine alone
Study: 20113920
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of HPV vaccine and dTpa-IPV
Study: 10944100
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants or aspirin after infrainguinal bypass surgery
Study: 26636426
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Processing Therapy - Cognitive only version (CPT-C)
Study: 25939018
Drug: Group Present-Centered
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Present-Centered Therapy (PCT)
Study: 22970177
Drug: Fully integrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully integrated services (ANC, PMTCT, and HIV treatment services all delivered in the ANC clinic)
Study: 22970177
Drug: Non-integrated services
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-integrated services (ANC clinics provided ANC and basic PMTCT services and referred clients to a separate HIV clinic for HIV treatment)
Study: 20233625
Drug: CA/AA versus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA/AA versus CC genotypes in C8092A in ERCC1
Study: 15531753
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP200), 200 microg daily for 3 months
Study: 11985942
Drug: Micronutrient-containing beverage
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient-containing beverage (12 oz daily for 6 weeks)
Study: 11985942
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 oz daily for 6 weeks)
Study: 28665038
Drug: M. chamomilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. chamomilla L., M. officinalis L. and tyndallized L. acidophilus (HA122) (Colimil® Plus®)
Study: 28665038
Drug: M. chamomilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. chamomilla L., M. officinalis L. and tyndallized L. acidophilus (HA122)
Study: 21412266
Drug: Candesartan (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (12 mg per day)
Study: 21412266
Drug: Candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (8 mg per day) plus amlodipine (2.5 mg per day)
Study: 17634896
Drug: MML group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MML group (moxifloxacin 400 mg/d, metronidazole 400 mg twice daily, lansoprazole 30 mg twice daily)
Study: 17634896
Drug: MAL group
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL group (moxifloxacin 400 mg/d, amoxicillin 1 g twice daily, lansoprazole 30 mg twice daily)
Study: 17634896
Drug: CML group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CML group (clarithromycin 500 mg twice daily, metronidazole 400 mg twice daily, lansoprazole 30 mg twice daily)
Study: 17634896
Drug: CAL group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAL group (clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily, lansoprazole 30 mg twice daily)
Study: 11722487
Drug: Topical skin
Normalized name: Betadine 7.5% Topical Skin Cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical skin lipid mixture containing ceramide‐3 and patented nanoparticles
Study: 11722487
Drug: Topical skin
Normalized name: Betadine 7.5% Topical Skin Cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical skin lipid mixture in combination with topical corticosteroids
Study: 11722487
Drug: Control (Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Topical corticosteroids alone)
Study: 372867
Drug: Diclofenac 25
Normalized name: diclofenac 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 25 mg q.i.d.
Study: 372867
Drug: Aspirin 750
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 750 mg q.i.d.
Study: 31989580
Drug: Behavioural change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural change programme plus moisturizing creams
Study: 28295451
Drug: GSK3050002 (0.1-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3050002 (0.1-20 mg kg-1)
Study: 28295451
Drug: GSK3050002 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3050002 (5 mg kg-1 and higher)
Study: 21193422
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg of vitamin K(1)
Study: 21193422
Drug: 150 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 μg of vitamin K(1)
Study: 21193422
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg of vitamin K(1)
Study: 15022805
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg cholestyramine-bound diclofenac (2 x 1 capsule Voltaren resinate) daily for 14 days
Study: 15022805
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg cholestyramine-bound diclofenac (1 x 1 capsule) daily for 14 days
Study: 15022805
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose (75 mg)
Study: 11255384
Drug: Nortriptyline (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (target steady-state level, 75-125 ng/mL) (n = 27)
Study: 11255384
Drug: Nortriptyline-lithium combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline-lithium combination (target steady-state level, 0.5-0.9 mEq/L) (n = 28)
Study: 9544650
Drug: Adjunctive mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive mitomycin C (MMC)
Study: 9544650
Drug: No adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjunctive mitomycin C (SGTP control)
Study: 2582838
Drug: Fenoterol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (400 micrograms, 600 micrograms, and 800 micrograms administered at 15-minute intervals, total dose 1.8 mg)
Study: 31609667
Drug: IPL +
Normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPL + RF combination therapy
Study: 31476481
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg, 2 doses: 2 hours before and 24 hours after surgery)
Study: 31476481
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 doses, 2 hours before and 24 hours after surgery)
Study: 17105693
Drug: Homeopathic arnica
Normalized name: ARNICA MONTANA WHOLE 6 [hp_X] ORAL LOZENGE [Homeopathic Arnica Drops]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic arnica (1 x 5 globules of dilution 30x before surgery and 3 x 5 globules daily after surgery)
Study: 17105693
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 x 5 globules before surgery and 3 x 5 globules daily after surgery)
Study: 24346102
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg LY293111
Study: 24346102
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg LY293111
Study: 18506165
Drug: Panitumumab alongside
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab alongside chemotherapy
Study: 29385147
Drug: Nabiximols (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabiximols (up to 113.4 mg THC/105 mg CBD)
Study: 24634423
Drug: Daily bathing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily bathing instructions
Study: 24634423
Drug: Twice a
Normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice a week bathing instructions
Study: 20585106
Drug: Modest reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modest reduction in salt intake from 9.7 to 6.5 g/day
Study: 10821362
Drug: High-dose L-folinic
Normalized name: L-Folinic acid
DrugBank: Levoleucovorin (DB11596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose L-folinic acid (175 mg)
Study: 10821362
Drug: Low-dose L-folinic
Normalized name: L-Folinic acid
DrugBank: Levoleucovorin (DB11596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose L-folinic acid (25 mg)
Study: 24822268
Drug: Levamisole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (50 mg)
Study: 8669651
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine by subcutaneous infusion (0.1 mg/kg/h)
Study: 8669651
Drug: Intermittent morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent morphine (0.1 mg/kg intravenously, four‐hourly)
Study: 31812149
Drug: EG-1962 (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: EG-1962 (sustained-release nimodipine) - 100-1200 mg as a single intraventricular injection
Study: 23350795
Drug: Insulin glargine,
Normalized name: insulin glargine, human recombin. analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin glargine, final mean dosage 0.44 units/kg, treatment duration 6 months
Study: 19678812
Drug: Oral bisacodyl
Normalized name: bisacodyl Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisacodyl (5 mg p.o. per day)
Study: 17432642
Drug: Medication (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Group D)
Study: 3325259
Drug: ofloxacin 800
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ofloxacin 800 mg once daily for 7 days
Study: 3325259
Drug: various new
Approvals — FDA: no, EMA: no, PMDA: no
Description: various new oral quinolones
Study: 27023594
Drug: 18% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18% of calories from high fructose corn syrup (HFCS)
Study: 18436904
Drug: On-demand drug
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand drug review
Study: 12610718
Drug: Immediate initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immediate initiation of 30 mg/day aripiprazole with simultaneous immediate discontinuation of current antipsychotic
Study: 12610718
Drug: Immediate initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immediate initiation of 30 mg/day aripiprazole while tapering off current antipsychotic over 2 weeks
Study: 12610718
Drug: Up-titrating aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Up-titrating aripiprazole to 30 mg/day over 2 weeks while simultaneously tapering off current antipsychotic
Study: 10639540
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU of vitamin E daily from natural sources
Study: 1347973
Drug: 1% apraclonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% apraclonidine solution
Study: 1347973
Drug: Formulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation with hydroxypropylmethylcellulose
Study: 1347973
Drug: Formulations with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations with hydroxypropylmethylcellulose or lysolecithin
Study: 31919989
Drug: Nintedanib (tyrosine-kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (tyrosine-kinase inhibitor)
Study: 24035211
Drug: Topical nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical nifedipine along with conventional treatment
Study: 24035211
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine and conventional treatment
Study: 21389845
Drug: Modified constraint‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint‐induced movement therapy (3 hrs/day, 5 days/wk for 4 weeks)
Study: 18420851
Drug: Haloperidol 2
Normalized name: haloperidol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2 mg (group H)
Study: 18420851
Drug: Dexamethasone 5
Normalized name: dexamethasone 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 5 mg (group Dx)
Study: 18420851
Drug: Haloperidol 2
Normalized name: haloperidol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2 mg plus Dexamethasone 5 mg (group H + Dx)
Study: 11023502
Drug: Donor lymphocyte
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor lymphocyte infusions (DLI) - bulk-dose (n = 34) or escalating-dose (n = 32) regimen
Study: 10944138
Drug: Donor lymphocyte
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor lymphocyte infusions (DLI)
Study: 1505611
Drug: Ethanol (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (high dose)
Study: 1505611
Drug: Ethanol (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (low dose)
Study: 1505611
Drug: Lorazepam (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (high dose)
Study: 1505611
Drug: Lorazepam (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (low dose)
Study: 1505611
Drug: Triprolidine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triprolidine (high dose)
Study: 1505611
Drug: Triprolidine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triprolidine (low dose)
Study: 6671847
Drug: Aversion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aversion therapy with covert imagery and electric shock
Study: 30689727
Drug: WHEY diet
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHEY diet (N = 10; 0.90 ± 0.01 g protein/kg/day)
Study: 30689727
Drug: MIXED diet
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIXED diet (N = 10; 0.97 ± 0.01 g protein/kg/day)
Study: 17050593
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza virus vaccine (LAIV)
Study: 17050593
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza virus vaccine (TIV)
Study: 9068813
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of killed Mycobacterium vaccae as immunotherapy after 1 month of treatment
Study: 9068813
Drug: Immunotherapy (M.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (M. vaccae)
Study: 31493382
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control group (dose-matched uninstructed practice)
Study: 28901216
Drug: Creatine (3g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (3g daily)
Study: 20039078
Drug: Ketamine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (both doses)
Study: 20090366
Drug: Desmopressin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin infusion
Study: 14522730
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (400 mL, 2.5 mmol chlorogenic acid/L)
Study: 14522730
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee (400 mL, 2.5 mmol chlorogenic acid/L)
Study: 14522730
Drug: Control (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (400 mL water)
Study: 1852471
Drug: Heparin 300
Normalized name: TAUROLIDINE 40.5 mg in 3 mL / HEPARIN 3000 [USP'U] in 3 mL INTRALUMINAL SOLUTION [DEFENCATH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 300 u/kg body weight intramuscularly once daily for 3 consecutive days
Study: 1852471
Drug: Dexamethasone 0.5
Normalized name: dexamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg/kg body weight intravenously, three times daily for three consecutive days
Study: 1852471
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no dexamethasone nor heparin)
Study: 24882606
Drug: Ultrasound-guided posterior
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided posterior TAP block using 15 mL of 0.375% ropivacaine on each side
Study: 24882606
Drug: Subcostal TAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcostal TAP block with 15 mL of 0.375% ropivacaine on each side
Study: 20663207
Drug: APC (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: APC (24 μg/kg/hour for 96 hours)
Study: 20663207
Drug: Placebo (similar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (similar infusion rate for 96 hours)
Study: 15854388
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg budesonide turbuhaler by inhalation every night (Group A)
Study: 15854388
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 5 mg/d and theophyllin control release tablet 0.2 g twice daily, as well as ventolin aerosol inhalation 200 microg three times daily during asthmatic attack (Group B)
Study: 15854388
Drug: Theophyllin control
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophyllin control release tablet 0.2 g twice daily and ventolin aerosol inhalation (200 microg/d) during asthmatic attack (Group C)
Study: 15854388
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone and theophyllin (Group B)
Study: 7650123
Drug: Starting dose
Normalized name: Austedo 6 MG Starting Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of two ampoules (150 IU) of human menopausal gonadotrophin (HMG) for 7 days (Group 1)
Study: 7650123
Drug: Starting dose
Normalized name: Austedo 6 MG Starting Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of three ampoules (225 IU) of human menopausal gonadotrophin (HMG) for 7 days (Group 2)
Study: 7650123
Drug: Starting dose
Normalized name: Austedo 6 MG Starting Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of three ampoules (225 IU) of human menopausal gonadotrophin (HMG) for 7 days (Group 3)
Study: 30563789
Drug: sublingual (SL)
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual (SL) delivery of double mutant heat-labile toxin LTR192G/L211A (dmLT) at doses of 1-50 µg
Study: 30563789
Drug: sublingual (SL)
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual (SL) delivery of dmLT at doses of 25 or 50 µg
Study: 30563789
Drug: sublingual (SL)
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual (SL) delivery of dmLT (3 doses at days 1, 15, and 29)
Study: 30563789
Drug: oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of dmLT
Study: 30563789
Drug: sublingual (SL)
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual (SL) and oral routes of dmLT
Study: 25857665
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT), 50 mL via enema from healthy anonymous donors, once weekly for 6 weeks.
Study: 25857665
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 mL water enema), once weekly for 6 weeks.
Study: 23686372
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg (escalated to 300 mg at 2 weeks)
Study: 19297248
Drug: Paracetamol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (6 g daily)
Study: 17708609
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum IL-18 levels (>= 10(5) pg/mL)
Study: 17708609
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum IL-18 levels (< 10(5) pg/mL)
Study: 15100587
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral analgesics (ketorolac, diclofenac potassium, bromfenac, tramadol, hydrocodone/ibuprofen fixed combination, celecoxib, rofecoxib, tramadol/acetaminophen, valdecoxib)
Study: 15100587
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral analgesics (5 of the 9 drugs)
Study: 15100587
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral analgesics
Study: 11535953
Drug: Misoprostol administered
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol administered into the posterior vaginal fornix (group M)
Study: 3556381
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of meptazinol
Study: 3556381
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of meptazinol
Study: 31309333
Drug: Lactobacillus Rhamnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus Rhamnosis GG (6 billion colony-forming unit per capsule) twice daily for 100 days
Study: 31309333
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for 100 days
Study: 28652529
Drug: Evacetrapib 130
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib 130 mg once daily for 12 weeks
Study: 26039494
Drug: Animal-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-assisted therapy (20 min session with an animal-assisted therapy dog after surgery)
Study: 23550779
Drug: Intracameral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral injection of Biolon (sodium‐hyaluronate 1%)
Study: 21747241
Drug: Valsartan/Hydrochlorothiazide 160/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Hydrochlorothiazide 160/12.5 mg combination therapy